PD-1 Blockers

Cell
Jedd D Wolchok

Abstract

Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung cancer.

References

Feb 27, 2001·Nature Immunology·Y LatchmanG J Freeman
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian

❮ Previous
Next ❯

Citations

Dec 22, 2015·Biochemical Pharmacology·Hans-Peter GerberChad May
Jun 1, 2016·Frontiers in Immunology·Emily R Mercadante, Ulrike M Lorenz
Jul 5, 2016·Nature Reviews. Genetics·Hubert HacklZlatko Trajanoski
Jul 2, 2016·Expert Opinion on Therapeutic Patents·Tryfon Zarganes-TzitzikasAlexander Dömling
Jul 28, 2016·Human Vaccines & Immunotherapeutics·William L Redmond, Stefanie N Linch
Nov 3, 2016·The New England Journal of Medicine·Douglas B JohnsonJavid J Moslehi
Feb 28, 2017·Cancer·Douglas B JohnsonAlexander M Menzies
May 26, 2017·Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology·Sho MiyamotoToshihiko Torigoe
Feb 28, 2017·Journal for Immunotherapy of Cancer·Eileen ShiuanDouglas Johnson
Apr 25, 2018·Drug Metabolism and Personalized Therapy·Sujit Nair, Adrián LLerena
Dec 14, 2017·Frontiers in Immunology·Mirjana EfremovaZlatko Trajanoski
May 1, 2018·Current Treatment Options in Cardiovascular Medicine·Inbar Agmon Nardi, Zaza Iakobishvili
Jul 6, 2018·Cancer·Douglas B Johnson
Oct 12, 2018·Cancer Science·Shogo NabeMasakatsu Yamashita
Oct 3, 2018·Hospital Practice·Diwakar Jain, Wilbert Aronow
Jan 24, 2018·The Cancer Journal·Daniel Y WangElizabeth J Davis
Apr 7, 2018·Case Reports in Oncological Medicine·Nora ChokrElizabeth Guadalupe
Jul 3, 2019·Expert Opinion on Pharmacotherapy·Nazanin Majd, John de Groot
Jan 27, 2020·Journal of Cellular and Molecular Medicine·Ting-Feng XiongXiang Zhou
Jul 6, 2017·Current Opinion in Oncology·Susanne G WarnerYuman Fong
Jun 12, 2020·Internal Medicine·Ryo FukudaYasuteru Kondo
Apr 19, 2019·Clinical Case Reports·Heather WalkerFrank Carey
Apr 10, 2020·Current Treatment Options in Oncology·Jason GraffagninoCarrie G Lenneman
May 26, 2017·Frontiers in Pharmacology·Jing HuangJindong Chen
Dec 17, 2016·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Jinru ShiaDavid S Klimstra
May 21, 2018·Journal of Neuro-oncology·Megan ManticaJan Drappatz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Cell eTOC

Cell is a scientific journal publishing research across a broad range of disciplines within the life sciences field. Discover the latest research from Cell here.